Manka-Waluch Agnieszka, Palmedo Holger, Reinhardt Michael J, Joe Alexius Y, Manka Christoph, Guhlke Stefan, Biersack Hans-Jürgen, Bucerius Jan
Department of Nuclear Medicine, University of Bonn, Bonn; Germany.
Ann Nucl Med. 2006 Dec;20(10):663-70. doi: 10.1007/BF02984677.
99mTc-tetrofosmin and 99mTc-sestamibi are approved tracers for myocardial perfusion studies. Recently, a 99mTc-MIBI preparation from a different manufacturer (99mTc-cardiospect-MIBI) has been introduced to the market. Therefore, the aim of this study was the evaluation of 99mTc-tetrofosmin as well as of two different 99mTc-labeled MIBI tracers with regard to differences in imaging quality under resting conditions.
Sixty patients (mean age 63.8 years +/- 1.25) with known or suspected coronary artery disease but without evidence of rest-ischemia were included. Twenty patients in each group were examined by a two-day-rest-stress protocol using the three 99mTc-labeled tracers. Visual analysis of all images was performed by two experienced physicians blinded with regard to the applied tracer. Regions of interest (ROI) were defined over the heart, lung and whole body only in the rest imaging in order to calculate heart-to-lung, lung-to-whole body-, and heart-to-whole body-ratios.
The heart-to-lung ratio was statistically significant higher for 99mTc-cardiospect-MIBI as compared to 99mTc-sestamibi as well as to 99mTc-tetrofosmin. Furthermore, a significantly higher heart-to-lung ratio was found for 99mTc-sestamibi as compared to 99mTc-tetrofosmin. The heart-to-whole body-ratio and the lung-to-whole body-ratio were equivalent between all tracers. Visual analysis revealed only slight differences regarding image quality between all tracers.
ROI analysis surprisingly revealed a significant higher myocardial uptake and consequently a higher heart-to-lung ratio for 99mTc-cardiospect-MIBI. Whether this leads to a better visual image quality has to be evaluated in future studies with larger study populations as well as semiquantitative segmental analysis of the myocardial perfusion images.
99m锝-替曲膦和99m锝-甲氧基异丁基异腈是已获批准用于心肌灌注研究的示踪剂。最近,一种来自不同制造商的99m锝-甲氧基异丁基异腈制剂(99m锝-心谱-MIBI)已投放市场。因此,本研究的目的是评估99m锝-替曲膦以及两种不同的99m锝标记的甲氧基异丁基异腈示踪剂在静息状态下成像质量的差异。
纳入60例已知或疑似冠心病但无静息缺血证据的患者(平均年龄63.8岁±1.25)。每组20例患者采用三日静息-负荷方案,使用三种99m锝标记的示踪剂进行检查。所有图像均由两名对所用示踪剂不知情且经验丰富的医生进行视觉分析。仅在静息显像时在心脏、肺和全身定义感兴趣区(ROI),以计算心-肺、肺-全身和心-全身比值。
与99m锝-甲氧基异丁基异腈以及99m锝-替曲膦相比,99m锝-心谱-MIBI的心-肺比值在统计学上显著更高。此外,与99m锝-替曲膦相比,99m锝-甲氧基异丁基异腈的心-肺比值显著更高。所有示踪剂的心-全身比值和肺-全身比值相当。视觉分析显示所有示踪剂之间在图像质量方面仅有细微差异。
感兴趣区分析令人惊讶地发现,99m锝-心谱-MIBI的心肌摄取显著更高,因此心-肺比值更高。这是否会带来更好的视觉图像质量,必须在未来更大规模研究人群的研究以及心肌灌注图像的半定量节段分析中进行评估。